D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Completed 54 enrolled Massachusetts General Hospital National Institute of Mental Health (NIMH) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

Timeline

Start: 2009-08
Primary completion: 2011-05
Completion: 2011-06

Outcome

Mixed primary results

paper Performance on the practiced auditory discrimination task significantly improved in the DCS group compared to the placebo group. PMID 24485587 ↗

paper However, improvement on the MATRICS battery was observed only in the placebo group. PMID 24485587 ↗

Publications

Results Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E, Goff DC. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr Res. 2014 Mar;153(1-3):177-83. doi: 10.1016/j.schres.2014.01.016. Epub 2014 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cycloserine	Small molecule	50 mg	Oral